What's so special about the layout of the research and development pipeline for the old drivers of pharmaceutical companies?

the | The year 2020 is destined to be an extraordinary year, this year began with the new crown epidemic, this RNA virus broke our way of life, masks have become our necessities, social distance has become the most popular words, a "do you do nucleic acid testing" to become a measure of human contact.
For the pharmaceutical industry this year is a special year, COVID-19 related vaccine development has become the object of public concern, has not been optimistic about the domestic pharmaceutical development capacity this year finally raised eyebrows, by the National Pharmaceutical Group Beijing Research Institute developed inactivated vaccine on December 31, 2020 approved the listing and free vaccination.
but we're not talking about COVID-19 today, and today we're going to talk about the layout of Amjin's 2020 product pipeline as a biopharmaceity giant.
pipeline distribution Amjin's 2020 product pipeline demonstrates its strong research and development and innovation capabilities.
22 of the 54 research and development pipelines were in Clinical Phase I, 6 in Clinical Phase II and 26 in Clinical Phase III.
"blood/tumor"-related product lines were the most abundant of all products, with 29 items, followed by 12 inflammation-related products.
Of all the drug types developed, single resistance, dual resistance and small molecular drug programs accounted for the highest proportion, monoanto-resistant drugs corresponding to the most widely distributed adaptive disorders, "blood/ tumor" drugs with the largest number of drug types.
distribution table is as follows.
bright spot drug analysis from the layout of the Amjin pipeline we can see several stars around the world have a great impact on the drug, these drugs once launched in the industry set off a huge wave.
such as AMG510 (SOTORASIB), Tezepelumab, Romosozumab.
AMG510 (SOTORASIB) Clinical Information Source: Pharmaceutical Intelligence Global Clinical Trials Database Pipeline Source: Amgen's official website through the Global Clinical Database of Pharmaceutical Intelligence and Amgen Pipeline shows that AMG510 is also in clinical research of three kinds of adaptations, namely non-small cell lung cancer, advanced colorectal cancer and other tumors, of which non-small cell lung cancer has entered the clinical stage 3.
AMG510 is the first drug to target KRAS G12C mutations, and the FDA has awarded AMG 510 orphan drugs designated for KRAS G12C-positive non-small cell lung and colorectal cancer, with 20% of KRAS in lung cancer with G12C mutations, and AMG510 opening a historic gap.
KRAS mutation as Oncogene has long been considered a kind of undruggable until 2019, when AMSco made the drug a hit with the KRAS G12C mutation by publishing stunning clinical trial data from AMG510.
if the tumor tissue contains KRAS mutations, patients will not be able to benefit from anti-EGFR medications and will only be able to opt for standard treatments such as chemotherapy.
but clinical data show that chemotherapy is inefficient for kras mutation patients, the remission time is short, and the therapeutic effect is very limited.
a 55-year-old male NSCLC patient who had tried almost all treatment options (including chemotherapy, erlotinib, PD1, dasatinib, M3541) failed, then used AMG510 (360mg), the tumor shrunk by 67%, and at 18 weeks of medication reached complete remission, the lesions had subsided to the extent that it could not be measured.
It is worth mentioning that in early 2020, Anjin company through the acquisition of a 20% stake in Baiji Shenzhou and Baiji Shenzhou reached a partnership, Baiji Shenzhou will be the world for solid tumors and hematomas and Anjin jointly developed 20 drugs, Anjin anti-tumor pipeline drugs, according to the current disclosure including AMG510.
helps more anti-tumor drugs enter the Chinese market.
Tezepelumab Drug Overview Source: Pharmaceutical Intelligence Data Pipeline Source: Ain's official website Tezepelumab has three registered filings, two of which are in the last year, and 47 clinical trials, three of which have been published in the last year.
Tezepelumab is currently studying two of the adaptations are severe asthma, chronic obstructive pulmonary disease, of which severe asthma has entered clinical phase III.
Tezepelumab, developed jointly by Amgen and AstraZeneca, is the first anti-TSLP monoantigen, and the U.S. Food and Drug Administration (FDA) has officially approved tezepelumab's breakthrough therapy drug for treating severe asthma patients without eosinophil ideotypes.
currently, listed asthma biologics are only available for certain types of asthma (i.e. subgroups of patients), such as acidophil asthma.
tezepelumab specifically binds to human TSLP and blocks its interaction with the subject complex, and due to its role in the early upstream of inflammatory cascading reactions, the drug has the potential to be used in a wide range of severe uncontrolled asthma patients, regardless of patient ideotype or T2 biomarker status.
the emergence of Tezepelumab is undoubtedly a triumphant victory for people with severe asthma.
Romosozumab Drug Overview Source: Pharmaceutical Intelligence Data Pipeline Source: Amjin's official website Romosozumab currently has four listings, 82 clinical trials, eight of which were released in the last year, and the drug's sales figures for 2019 are 238.257 million yuan.
Romosozumab is currently clinically studying osteoporosis in men, and as early as March 2019, romosozumab was launched in Japan to reduce the risk of fractures and increase bone density in men at high risk of fractures and post-menopaian female osteoporosis patients.
same month, the FDA officially approved the listing of romosozumab for the treatment of osteoporosis, which is associated with a high risk of fractures in post-menopatis women, and registered a product called ®.
is ® the world's first approved anti-sclerostin monoclonal antibody drug.
currently developed by domestic pharmaceutical giant Hengrui Pharmaceuticals of the same kind of anti-sclerostin monoclonal antibody drug SHR-1222 in the clinical phase I in the domestic field in a leading position.
Conclusion Through the initial observation of Amgen's pipeline layout, we can see that, as a global biopharmacemic giant enterprise, its product pipeline distribution body to solve cancer and inflammatory diseases as the main body, the use of a variety of platforms to develop drugs its drug types involving monoantigen, dual resistance, small molecules and other types.
at the same time, as it was hit by the market for bioso-like drugs, it made its first effort to develop the first drugs, such as AMG510, which made the industry a sensation.
In the Chinese market, as a multinational giant in the progress of the Chinese market is relatively slow, but good in its grasp of the Chinese mouth aging opportunities, the Chinese market for cardiovascular diseases, bone health, tumors, inflammation and chronic diseases of the drug demand is increasing year by year.
benefited from the dividends of the policy, the company's cardiovascular disease drug "Eloyu monoanti" and the drug used to treat osteoblastoma, "Dshu monoantigen injection", were launched in China in January and May 2019, respectively.
cooperation with Baiji Shenzhou also lays the foundation for the future promotion of its products in China.
believe that in the future, more and more multinational pharmaceutical giants will cooperate with local Chinese enterprises to contribute to the development of China's drug development and health industry.
encourage Chinese companies to create more and more innovative drugs.